Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment

CONCLUSION: In the first-line treatment, combination regimen has advantages over single regimen. Among them, chemotherapy combined with immunotherapy plus antiangiogenic therapy can achieve significant efficacy benefits.PMID:38625494 | DOI:10.1007/s12094-024-03485-6

Source: Cancer Control - April 16, 2024 Category: Cancer & Oncology Authors: Ke Wang Manyi Xu Yanhua Wang Chunwei Xu Yue Hao Zhengbo Song Source Type: research